More on UNCY

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (+23.9% Growth)
- Ratings (10.0 Score)

Upcoming Events

- Earnings (11/18/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Unicycive Therapeutics, Inc (NQ:UNCY)
Delayed: 3.89 -0.05 (1.27%)
Prev. Close $3.94  
Open$3.95 
52 Wk High$ 
52 Wk Low$ 
Day High$4.02 
Day Low$3.71 
P/E N/A  
EPS$ 
Volume1,212,426 

Friends, Peers and Foes (?): FIVE, HUM, MOH, SLNO, APLT (more...)

Oct 22, 2026 01:14 PM FDA accepts Unicycive's OLC resubmission with March 2027 action date
Oct 22, 2026 01:14 PM Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate NDA Resubmission and PDUFA Date of March 25, 2027
Oct 21, 2026 09:31 PM FDA accepts Unicycive's OLC drug resubmission with March 2027 review date
Oct 21, 2026 09:31 PM Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate NDA Resubmission and PDUFA Date of March 25, 2027
Oct 21, 2026 07:59 PM FDA accepts Unicycive's OLC resubmission, sets March 2027 review date
Oct 21, 2026 07:59 PM Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate NDA Resubmission and PDUFA Date of March 25, 2027
Oct 21, 2026 09:33 AM Unicycive stock jumps as FDA accepts OLC drug resubmission
Oct 21, 2026 07:05 AM FDA accepts Unicycive's OLC drug resubmission, sets March 2027 review date
Oct 21, 2026 07:05 AM Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate New Drug Application Resubmission and PDUFA Date of March 25, 2027
Oct 20, 2026 04:17 PM INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Unicycive Therapeutics, Inc. to Contact Law Firm
View All Articles

Entities mentioned with UNCY

View All Entities